So, what is better about what IFRX is doing? A key point that should be noted is there doesn't seem to be a lot of overlap in disease indications between the two as CCXI is specifically targeting aHUS and C3G whereas IFRX is targeting hidradenitis suppurativa with the lead indication (but also targeting AAV which is lead indication for avacopan).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.